GlassScriptPhysician profile
Malini Gupta
NPI 1164626248
$90,889.97
in general payments reported to CMS, 2019-2025
47 companies · $55K in 2025
The $55K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $1,913 · 2021: $1,124 · 2022: $2,822 · 2023: $20K · 2024: $8,485 · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Honoraria: $26K · Food and Beverage: $8,292 · Travel and Lodging: $7,130 · Consulting Fee: $5,320 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,427.20 |
| Honoraria | $25,737.10 |
| Food and Beverage | $8,291.81 |
| Travel and Lodging | $7,130.28 |
| Consulting Fee | $5,320.00 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $27,549.88 | 2024-2025 | Mycapssa, Myalept, Juxtapid |
| Amgen INC. | $25,385.52 | 2019-2025 | Tepezza, Repatha |
| Horizon Therapeutics Plc | $19,650.60 | 2019-2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $7,498.10 | 2025 | Yorvipath |
| Novo Nordisk INC | $2,509.92 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Ibsa Pharma INC. | $2,163.13 | 2019-2025 | Tirosint, Licart, Flector |
| Eisai INC. | $1,766.49 | 2019-2025 | |
| Corcept Therapeutics | $760.06 | 2019-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.40 | 2019-2023 | Cycloset |
| Abbvie INC. | $411.95 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.50 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $265.04 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $216.32 | 2019-2022 | |
| Sequel Med Tech, LLC | $208.67 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $159.91 | 2021-2025 | Recorlev, Gvoke Hypopen |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malini Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.